Cross-sectional study to identify candidates for systemic therapy in adult patients with atopic dermatitis (ADopt, H21-139)

• Conditions: L20; Atopic dermatitis

• Registration Number: DRKS00023296
• Lead Sponsor: AbbVie Deutschland GmbH & Co. KG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-01-22
• Study Completion: 2021-10-14
• Results First Posted: 2023-08-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 587

Inclusion Criteria

Physician’s confirmed diagnosis of atopic dermatitis
-Adult patients, age = 18 years
-Medication history of atopic dermatitis therapies available within the past 12 months
-Patient able to understand the questionnaires
-Patient willing to provide written consent to the patient authorization form to use and disclose personal health information

Exclusion Criteria

-Patient is currently participating in interventional clinical trial(s)
-Patient refuses to provide written consent to the patient authorization form to use and disclose personal health information

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- In patients currently not receiving systemic AD therapy: Proportion of patients who are eligible for a systemic atopic dermatitis (AD) therapy according to the selection criteria of the German guideline.<br><br>- In patients currently receiving systemic AD therapy: Proportion of patients who are eligible for a switch of systemic AD therapy according to the selection criteria of the German guideline.